High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients

By J. Llitjos, Maxime Leclerc, Camille Chochois, J. Monsallier, M. Ramakers, M. Auvray, K. Merouani. Journal of Thrombosis and Haemostasis, 2020

1,067 citations recorded by the source corpus.

Coagulopathy is a common abnormality in patients with COVID‐19. However, the exact incidence of venous thromboembolic event is unknown in anticoagulated, severe COVID‐19 patients.

Subfields: Infectious Diseases, Internal Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/9d7c0493edc68d6cf388d55a2f2e99a17b56b7f2

Citations in the corpus

• Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis (2020, neutral): “Some studies have reported TE rates in the range of 20 (cid:1) 30% [4 (cid:1) 6] while others have reported rates as high as 40 (cid:1) 70% [7 (cid:1) 9].”
• Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 (2020, neutral): “Bacterial infections can occur in patients with severe COVID-19 (Chen et al., 2020c; Llitjos et al., 2020) and were present in some of our patients with severe disease but did not significantly modify the profile of released proteins (Figures S5B and S5C), including calprotectin (Figure 5F).”